

October 17, 2025

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C-1, G- Block,
Bandra - Kurla Complex, Bandra (East)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers,
Dalal Street,
Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of Press Release with respect to Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025.

Kindly take the above on record.

Thanking you,

Yours Sincerely,
For RPG Life Sciences Limited

Rajesh Shirambekar
Head – Legal & Company Secretary

Encl.: as above



Q2 FY26: Revenue up by 7.6% Q-o-Q. EBITDA margin at 24.0%

Mumbai, 17 October, 2025: RPG Life Sciences Limited has announced its financial results for the second quarter and half year ended September 30, 2025.

Q2 FY26 Highlights	Q-o-Q Revenue from operations
	Rs. 181.7 crores vs. Rs. 168.9 crores
Q2 FY26 Highlights	Y-o-Y Revenue from operations
	Rs. 181.7 crores vs. Rs. 172.2 crores
H1 FY26 Highlights	Rs. 350.6 crores vs. Rs. 337.6 crores

In Q2 FY26, RPG Life Sciences recorded a 7.6% Q-o-Q and 5.5% Y-o-Y increase in revenue. EBITDA margins stood at a strong 24%, reflecting operational efficiency. For H1 FY26, revenue grew by 3.8% Y-o-Y, maintaining strong operational momentum.

Commenting on the results as well as the outlook of the business, Mr. Ashok Nair, Managing Director, RPG Life Sciences Ltd. said, “In Q2, we have further strengthened our growth trajectory, driven by disciplined execution and a clear strategic focus. Our domestic formulations business is delivering market-beating performance with a growth of 13.5% in H1 FY26 versus Indian Pharma Market which recorded a growth of 7.4% in H1. Our transformation agenda is anchored in a legacy of quality and focused on enhancing patient outcomes. We are making steady progress in our International Formulations and API business, supported by new customer acquisitions, expansion into both emerging and regulated markets, and launch of molecules that enhance our therapeutic footprint.”

“We remain committed to building a future-ready pharmaceutical enterprise—one that delivers patient happiness through innovation and trust, embraces a people-first culture, and consistently delivers sustainable value to patients, partners, and stakeholders,” added Nair.

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences is an integrated research-based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company produces a wide range of quality and affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Group (www.rpggroup.com):

RPG Group, established in 1979, is one of India’s fastest-growing business groups with a turnover of US\$ 5.2 billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

Media Contact: Rashmi Menon – 88980 20577 | rashmi@rpg.in